Clinical trial

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression

NCT04670081

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Psilocybin Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Nicotinamide Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2021-06-10

PhasePHASE2

Conditions

Treatment-resistant Depressionunresolved

Interventions

PsilocybinDRUG

NicotinamideDRUG

Sponsors & collaborators

Central Institute of Mental Health, Mannheimlead sponsor

Charite University, Berlin, Germanycollaborator

MIND Foundation gGmbHcollaborator

German Federal Ministry of Education and Researchcollaborator

Usona Institutecollaborator

Mapped research locations

BerlinGermany1 MannheimGermany1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04670081 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.